These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32311605)

  • 21. Corrigendum to "Synthesis and evaluation of 2,5-furan, 2,5-thiophene and 3,4-thiophene-based derivatives as CXCR4 inhibitors" [Eur. J. Med. Chem. 181 (2019) 111562].
    Gaines T; Garcia F; Virani S; Liang Z; Yoon Y; Oum YH; Shim H; Mooring SR
    Eur J Med Chem; 2023 Dec; 261():115753. PubMed ID: 37634992
    [No Abstract]   [Full Text] [Related]  

  • 22. Corrigendum to "Synthesis and preliminary antiproliferative activity of new pteridin-7(8H)-one derivatives" [Eur. J. Med. Chem. 143 (2018) 1396-1405].
    Li ZH; Zhao TQ; Liu XQ; Zhao B; Wang C; Geng PF; Cao YQ; Fu DJ; Jiang LP; Yu B; Liu HM
    Eur J Med Chem; 2019 Nov; 181():111387. PubMed ID: 31376565
    [No Abstract]   [Full Text] [Related]  

  • 23. Corrigendum to: Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib [Eur. J. Med. Chem. 172 (2019) 143-153].
    Poratti M; Marzaro G
    Eur J Med Chem; 2020 Jun; 195():112272. PubMed ID: 32251743
    [No Abstract]   [Full Text] [Related]  

  • 24. Corrigendum to 'Dihydroorotate dehydrogenase: A drug target for the development of antimalarials' [Eur. J. Med. Chem. 125 (2017) 640-651].
    Singh A; Maqbool M; Mobashir M; Hoda N
    Eur J Med Chem; 2017 Mar; 128():346-347. PubMed ID: 28241929
    [No Abstract]   [Full Text] [Related]  

  • 25. Corrigendum to "Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview" [Eur. J. Med. Chem. 194 (2020) 112260].
    Mondal S; Adhikari N; Banerjee S; Amin SA; Jha T
    Eur J Med Chem; 2020 Nov; 205():112642. PubMed ID: 32750565
    [No Abstract]   [Full Text] [Related]  

  • 26. Corrigendum to "Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity" [Eur. J. Med. Chem. 122 (2016) 232-246].
    Gaura R; Pathania AS; Malik FA; Bhakuni RS; Verma RK
    Eur J Med Chem; 2022 May; 235():114277. PubMed ID: 35344906
    [No Abstract]   [Full Text] [Related]  

  • 27. Corrigendum to "Discovery of novel nonsteroidal VDR agonists with novel diarylmethane skeleton for the treatment of breast cancer" [Eur. J. Med. Chem. 163 (2019) 787-803].
    Wang C; Wang B; Hou S; Xue L; Kang Z; Du J; Li Y; Liu X; Wang Q; Zhang C
    Eur J Med Chem; 2020 Jan; 186():111907. PubMed ID: 31791642
    [No Abstract]   [Full Text] [Related]  

  • 28. Corrigendum to "Identification of novel β-lactams and pyrrolidinone derivatives as selective Histamine-3 receptor (H3R) modulators as possible anti-obesity agents" [Eur. J. Med. Chem. 152 (2018) 148-159].
    Ghoshal A; Kumar A; Yugandhar D; Sona C; Kuriakose S; Nagesh K; Rashid M; Singh SK; Wahajuddin M; Yadav PN; Srivastava AK
    Eur J Med Chem; 2018 Aug; 156():628-630. PubMed ID: 30031973
    [No Abstract]   [Full Text] [Related]  

  • 29. Design, Synthesis and Evaluation of Novel 3/4-((Substituted benzamidophenoxy) methyl)-N-hydroxybenzamides/propenamides as Histone Deacetylase Inhibitors and Antitumor Agents.
    Anh DT; Thuan NT; Hai PT; Huong LT; Yen NTK; Han BW; Park EJ; Choi YJ; Kang JS; Hue VTM; Han SB; Nam NH
    Anticancer Agents Med Chem; 2019; 19(4):546-556. PubMed ID: 30426904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Corrigendum to"Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo"[Eur. J. Med. Chem. 190 (2020 Mar 15) 112086].
    Ojha R; Nepali K; Chen CH; Chuang KH; Wu TY; Lin TE; Hsu KC; Chao MW; Lai MJ; Lin MH; Huang HL; Chang CD; Pan SL; Chen MC; Liou JP
    Eur J Med Chem; 2020 Sep; 201():112404. PubMed ID: 32526554
    [No Abstract]   [Full Text] [Related]  

  • 31. Corrigendum to "Synthesis of the pH-sensitive nanoparticles based on the acylhydrazone bonds conjugated doxorubicin and studies on their in vivo anti-tumor effects" [Eur. J. Med. Chem. 260 (2023) 115715].
    Shi Y; Pan X; Xu S; Zhu H; Zhao B; Sun Z; Dong R; Li N; Hou X; Yang X
    Eur J Med Chem; 2023 Dec; 262():115887. PubMed ID: 37867086
    [No Abstract]   [Full Text] [Related]  

  • 32. Corrigendum to"An insight into the medicinal perspective of synthetic analogs of indole: A review" [Eur. J. Med. Chem. 180 (2019) 562-612 11516].
    Thanikachalam PV; Maurya RK; Garg V; Monga V
    Eur J Med Chem; 2019 Dec; 183():111680. PubMed ID: 31520927
    [No Abstract]   [Full Text] [Related]  

  • 33. Corrigendum to "Optimization of physicochemical properties for 4-Anilinoquinazoline inhibitors of trypanosome proliferation" [Eur. J. Med. Chem. 141 (2017) 446-459].
    Woodring JL; Bachovchin KA; Brady KG; Gallerstein MF; Erath J; Tanghe S; Leed SE; Rodriguez A; Mensa-Wilmot K; Sciotti RJ; Pollastri MP
    Eur J Med Chem; 2018 May; 152():515. PubMed ID: 29754075
    [No Abstract]   [Full Text] [Related]  

  • 34. Corrigendum to "Photocytotoxic oxovanadium(IV) complexes of ferrocenyl-terpyridine and acetylacetonate derivatives" [Eur. J. Med. Chem. 92 (2015) 332-341].
    Balaji B; Balakrishnan B; Perumalla S; Karande AA; Chakravarty AR
    Eur J Med Chem; 2019 Aug; 175():1. PubMed ID: 31055148
    [No Abstract]   [Full Text] [Related]  

  • 35. Corrigendum to "Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity" [Eur. J. Med. Chem. 55 (2012) 220-227].
    Chen KF; Tai WT; Hsu CY; Huang JW; Liu CY; Chen PJ; Kim I; Shiau CW
    Eur J Med Chem; 2018 Jan; 143():2015. PubMed ID: 29113744
    [No Abstract]   [Full Text] [Related]  

  • 36. Corrigendum to "6-Amino-2,4,5-trimethylpyridin-3-ols: A new general synthetic route and antiangiogenic activity" [Eur. J. Med. Chem. 74 (2014) 126-139].
    Kim DG; Kang Y; Lee H; Lee EK; Nam TG; Kim JA; Jeong BS
    Eur J Med Chem; 2017 Dec; 141():734-735. PubMed ID: 28988929
    [No Abstract]   [Full Text] [Related]  

  • 37. Corrigendum to "Discovery of orally active anticancer candidate CFI-400945 derived from biologically promising spirooxindoles: Success and challenges" [Eur. J. Med. Chem. 95 (2015) 35-40].
    Yu B; Yu Z; Qi PP; Yu DQ; Liu HM
    Eur J Med Chem; 2016 Nov; 124():248. PubMed ID: 27592393
    [No Abstract]   [Full Text] [Related]  

  • 38. Corrigendum to "From irreversible to reversible covalent inhibitors: Harnessing the andrographolide scaffold for anti-inflammatory action" [Eur. J. Med. Chem. 204 (2020) 112481].
    Tran QTN; Tan DWS; Wong WSF; Chai CLL
    Eur J Med Chem; 2021 Jan; 209():112943. PubMed ID: 33097302
    [No Abstract]   [Full Text] [Related]  

  • 39. Corrigendum to "1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma" [Eur. J. Med. Chem. 140 (2017) 84-91].
    Liu YM; HuangFu WC; Huang HL; Wu WC; Chen YL; Yen Y; Huang HL; Nien CY; Lai MJ; Pan SL; Liou JP
    Eur J Med Chem; 2020 Sep; 202():112633. PubMed ID: 32688164
    [No Abstract]   [Full Text] [Related]  

  • 40. Corrigendum to "Discovery of new azoles with potent activity against Candida spp. and Candida albicans biofilms through virtual screening" [Eur. J. Med. Chem. 179 (2019) 634-648].
    Sari S; Kart D; Öztürk N; Kaynak FB; Gencel M; Taşkor G; Karakurt A; Saraç S; Eşsiz Ş; Dalkara S
    Eur J Med Chem; 2020 Mar; 190():112130. PubMed ID: 32074493
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.